Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
Abstract As trials of immune checkpoint inhibitor (ICI) therapies demonstrate responses in only a minority of pleural mesotheliomas (PlMs) and largely exclude patients with the related peritoneal mesothelioma (PeM), clinicians need predictive biomarkers of response and inclusion of PeM patients in f...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-03-01
|
| Series: | Genome Medicine |
| Online Access: | http://link.springer.com/article/10.1186/s13073-019-0631-0 |